Analysts Set Price Target for Medpace Holdings at $486.67

Shares of Medpace Holdings, Inc. (NASDAQ:MEDP) have received an average rating of “Hold” from fifteen analysts following the company, according to data from Marketbeat.com. The consensus includes one sell rating, nine hold ratings, and five buy ratings. The average price target set by these analysts stands at $486.67 for the upcoming year.

Several major brokerage firms have issued reports on Medpace, reflecting varying views on the stock. On February 11, 2024, Mizuho established a price target of $582.00. Subsequently, on February 18, 2024, TD Cowen upgraded Medpace from a “sell” to a “hold” rating, adjusting their price target downwards from $462.00 to $419.00. On March 6, 2024, Barclays changed its rating from “underweight” to “equal weight” with a new price target of $500.00. Meanwhile, Jefferies Financial Group upgraded the stock from a “hold” to a “buy” rating with a price objective of $560.00 on February 13, 2024. BMO Capital Markets also reaffirmed a “market perform” rating on the same day as Mizuho’s report.

Recent Earnings and Growth Potential

Medpace recently reported its earnings results for the quarter ending February 9, 2024, posting earnings per share (EPS) of $4.67. This figure surpassed the consensus estimate of $4.18 by $0.49. The company’s revenue reached $708.45 million, exceeding analyst expectations of $689.53 million. Medpace’s return on equity was reported at 118.82%, with a net margin of 17.83%. Compared to the same quarter last year, the company’s revenue showed significant growth at 32.0%, up from $3.67 EPS in the previous fiscal period.

Looking ahead, Medpace has set guidance for fiscal year 2026 with an anticipated EPS range of 16.680 to 17.500. Analysts project that the company will report 12.29 EPS for the current year, indicating continued optimism about its financial performance.

Institutional Investor Activity

Recent changes in institutional ownership reflect growing interest in Medpace. Notably, Quent Capital LLC entered a new position during the third quarter valued at approximately $25,000. Similarly, Optiver Holding B.V. acquired a new stake valued at around $27,000. Geneos Wealth Management Inc. increased its holdings by 64.9% in the first quarter, bringing its total to 94 shares worth about $29,000. Other notable investments include Steigerwald Gordon & Koch Inc. and Elyxium Wealth LLC, both acquiring new stakes in the fourth quarter, each valued at approximately $30,000.

Currently, institutional investors hold approximately 77.98% of Medpace’s stock, indicating strong institutional confidence in the company’s long-term growth potential.

Medpace Holdings, Inc. operates as a global contract research organization (CRO), providing a range of comprehensive clinical development services to biotechnology, pharmaceutical, and medical device companies. The firm supports clinical trials across all phases, offering end-to-end solutions aimed at expediting the development of new therapies. Core services include clinical pharmacology, regulatory affairs consulting, project management, and data management, among others.

The outlook for Medpace remains positive as analysts and investors closely monitor its performance and strategic direction in the evolving healthcare landscape.